Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Table S2 from A Phase II Study of Docetaxel and Pembrolizumab plus Interleukin 12 Gene Therapy in Nonmetastatic, Anthracycline-Refractory Triple-Negative Breast Cancer (INTEGRAL)
  1. Home
  2. Publications
  3. Supplementary Table S2 from A Phase II Study of Docetaxel and Pembrolizumab plus Interleukin 12 Gene Therapy in Nonmetastatic, Anthracycline-Refractory Triple-Negative Breast Cancer (INTEGRAL)

Supplementary Table S2 from A Phase II Study of Docetaxel and Pembrolizumab plus Interleukin 12 Gene Therapy in Nonmetastatic, Anthracycline-Refractory Triple-Negative Breast Cancer (INTEGRAL)

Authors:
  • PNPolly Niravath
    Polly Niravath
  • IUIvonne Uzair
    Ivonne Uzair
  • KSKai Sun
    Kai Sun
  • HMHanh Mai
    Hanh Mai
  • JGJian Guan
    Jian Guan
  • MLMailin Li
    Mailin Li
  • JDJenying Deng
    Jenying Deng
  • WQWei Qian
    Wei Qian
  • JZJianying Zhou
    Jianying Zhou
  • LGLiliana Guzman
    Liliana Guzman
  • KBKelsey Banaglorioso
    Kelsey Banaglorioso
  • RHRabia Hashmani
    Rabia Hashmani

Open Access
Publisher website
Google Scholar
  • 17 June 2026
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/1078-0432.32711111
Abstract
Supplementary Table 2: Representativeness of Study Participants
Keywords
  • SUPPLEMENTARY TABLE
  • GENE THERAPY
  • BREAST CANCER
  • STUDY PARTICIPANTS
  • TRIPLE-NEGATIVE BREAST
  • ANTHRACYCLINE-REFRACTORY TRIPLE-NEGATIVE
  • TABLE
  • SUPPLEMENTARY
  • INTEGRAL
  • INTERLEUKIN
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.